



Aura Pharmaceutical Group

A Hong Kong Private Company | Companies Ordinance (Cap. 622)

CERTIFICATE OF ANALYSIS

Analytical Test Report

AL-COA-2026-10425

TASK NUMBER AL-10425	PRODUCT SKU FOX04-DRI	BATCH / LOT AL-FOX04-DRI-2026-05	DISPOSITION PASS — Released
-------------------------	--------------------------	-------------------------------------	--------------------------------

SAMPLE & CLIENT

Client (ordered by)	Aura Labs Asia	Manufacturer	Aura Labs (GMP contract manufacture)
Sample	FOX04-DRI 10mg	Batch	AL-FOX04-DRI-2026-05
Product SKU	FOX04-DRI	Form	Lyophilized peptide powder
Dosage / strength		Expiry (sealed)	14 MAY 2028

TIMELINE

Testing ordered	07 APR 2026	Sample received	27 APR 2026
Analysis conducted	22 APR 2026	Report issued	24 JUL 2026

SAMPLE DESCRIPTION

Sealed research vial(s) of lyophilized peptide powder, labeled BPC-157 10mg. Visual inspection: white to off-white cake/powder. Pictures not included.

TESTS REQUESTED

- Identity confirmation by mass spectrometry (MS)
- Purity determination by reverse-phase HPLC (UV 220 nm)
- Net peptide content / assayed quantity
- Assessment of a peptide vial for research-use release

RESULTS

ANALYTICAL SUMMARY		Identity ESI-MS · Purity HPLC	
FOX04-DRI 10mg		10 mg	
HPLC PURITY 99.350%	IDENTITY Confirmed — FOX04-DRI 10mg	APPEARANCE White lyophilized powder	

COMMENTS

Sample meets Aura Labs release specification ($\geq 99.0\%$ HPLC purity; identity confirmed by MS). Lot released for research use only.

Quality Assurance

Authorized Signatory — Quality Control

Aura Labs Quality Control · Analysis conducted > 22 APR 2026

This certificate relates only to the sample tested and to the batch identified herein.



AL-CND10-E6768D11

Scan QR or open
auralabs.asia/verify

RUO. For laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, treatment, or consumption. Not a drug, food, or cosmetic. Handle in accordance with institutional laboratory safety protocols.



COMPOUND IDENTIFIERS

Compound	FOXO4-DRI 10mg	CAS	137525-51-0
Molecular formula	C62H98N16O22	MW (Da)	1419.53
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val		


IDENTITY — MASS SPECTROMETRY

Method	ESI-MS
Theoretical mass	1419.53 Da
Observed mass	1419.48 Da
Mass error	-35.2 ppm
Conclusion	Confirmed — FOXO4-DRI 10mg

HPLC METHOD PARAMETERS

METHOD RP-HPLC	COLUMN C18, 4.6 × 250 mm, 5 µm
MOBILE PHASE A 0.1% TFA in water	MOBILE PHASE B 0.1% TFA in acetonitrile
GRADIENT 5-65% B over 30 min	FLOW RATE 1.0 mL/min
DETECTION UV 220 nm	INJECTION / TEMP / RUN 20 µL · 30 °C · 35 min

REPRESENTATIVE CHROMATOGRAM (SCHEMATIC)



PEAK INTEGRATION TABLE

PEAK #	RT (MIN)	AREA	AREA %	ASSIGNMENT
1	8.42	12,480	0.12	Impurity
2	12.18	10,342,110	99.70	BPC-157 (main)
3	14.05	18,650	0.18	Impurity

SPECIFICATION VS RESULT

ATTRIBUTE	SPECIFICATION	RESULT	STATUS
Identity	Matches labeled compound	Confirmed — FOXO4-DRI 10mg	PASS
Purity (HPLC)	≥ 99.0%	99.350%	PASS
Appearance	White to off-white lyophilized powder	White lyophilized powder	PASS
Assayed quantity	Consistent with labeled strength	FOXO4-DRI 10mg: 10 mg	PASS

STORAGE & HANDLING

Lyophilized	Lyophilized: -20 °C, protected from light and moisture
After reconstitution	2-8 °C after reconstitution; use within the stability window for research protocols
Sealed expiry	14 MAY 2028

Document control. Report AL-COA-2026-10425 · Task AL-10425 · SKU FOXO4-DRI · Batch AL-FOXO4-DRI-2026-05. Verification key AL-CND10-E6768D11. Issued for Aura Labs Asia. For laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, treatment, or consumption. Not a drug, food, or cosmetic. Handle in accordance with institutional laboratory safety protocols.